SCHEMBL31292467

SCHEMBL31292467

CC(C)(C(=O)O)c1cccc(C(N)=O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
KMT2A Q03164 1/20 0.53
PARP1 P09874 8/20 0.52
KIF11 P52732 3/20 0.50
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ACHE P22303 3/20 0.45
PARP15 Q460N3 1/20 0.42
PARP10 Q53GL7 1/20 0.42
OPRK1 P41145 1/20 0.42
KCNH2 Q12809 1/20 0.42
DHODH Q02127 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158786 0.85 RXRA (0.53) KIF11POLBHSD17B10ACHE
SCHEMBL27989141 0.83 PARP1 (0.57) MAPTKMT2APARP1KIF11POLB
SCHEMBL179447 0.83 ACHE (0.62) MAPTKMT2APARP1KIF11POLB
Acetic Acid SCHEMBL4631451 0.82 ACHE (0.57) MAPTKMT2APARP1KIF11POLB
SCHEMBL7488968 0.82 ATM (0.59) MAPTCYP3A4RECQLPMP22HSD17B10
SCHEMBL27787452 0.81 PARP1 (0.55) MAPTKMT2APARP1KIF11POLB
SCHEMBL30112011 0.81 PARP1 (0.55) MAPTKMT2APARP1KIF11POLB
SCHEMBL8324897 0.81 PARP1 (0.60) MAPTKMT2APARP1KIF11POLB
SCHEMBL31510753 0.81 KMT2A (0.50) MAPTKMT2APARP1KIF11POLB
SCHEMBL3600911 0.80 ACHE (0.54) MAPTKMT2APARP1KIF11ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 US disclosed
WO-2025024521-A1 SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS, INC. (US) 2025-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MAPT 389/4885KMT2A 3318/4885PARP1 1134/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 MAPT 383/4885KMT2A 3301/4885PARP1 1129/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MAPT 389/4885KMT2A 3318/4885PARP1 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.